Table 2.
Clinicopathological factors with the status of LAT1 (n = 143).
| Pre LAT1 | PostLATl | |||||
|---|---|---|---|---|---|---|
| Total score | Total score | |||||
| Mean | SD | P value | Mean | SD | P value | |
| Total | 14.5 (0–30) | 9.71 | 10.6 (0–30) | 7.74 | ||
| Pre cT | ||||||
| 1/2 | 15.4 | 0.91 | 0.0403* | 11.2 | 0.83 | 0.1570 |
| 3/4 | 11.6 | 1.67 | 8.8 | 1.43 | ||
| PrecN | ||||||
| 0 | 18.1 | 2.16 | 0.0806 | 12.4 | 2.23 | 0.4091 |
| 1 < | 14.0 | 0.86 | 10.4 | 0.76 | ||
| Pre cStage | ||||||
| O/I/II | 15.4 | 0.94 | 0.0867 | 11.3 | 0.85 | 0.1530 |
| nr/vi | 12.3 | 1.54 | 9.0 | 1.34 | ||
| Pre ER | ||||||
| Positive | 13.1 | 1.02 | 0.0229* | 10.3 | 0.87 | 0.5293 |
| Negative | 16.9 | 1.29 | 11.3 | 1.27 | ||
| Pre PR | ||||||
| Positive | 13.2 | 1.11 | 0.0831 | 9.7 | 0.92 | 0.1185 |
| Negative | 16.0 | 1.16 | 12.0 | 1.13 | ||
| Pre HER2 | ||||||
| Positive | 16.8 | 1.58 | 0.0967 | 9.5 | 0.83 | 0.3792 |
| Negative | 13.7 | 0.93 | 11.0 | 1.46 | ||
| PostKi-67 LI | ||||||
| High | 15.5 | 1.17 | 0.0301* | 12.2 | 0.94 | 0.0256* |
| (Cut off 9.6) Low | 11.6 | 1.34 | 9.0 | 1.07 | ||
| Post SUV max | ||||||
| High | 15.8 | 1.44 | 0.0140* | 10.7 | 1.41 | 0.6198 |
| (Cut off 2) Low | 20.1 | 0.89 | 9.8 | 1.02 | ||
LAT1, L-type amino acid transporter-1, SLC7A5; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2 ; SUV, standardized uptake value.
The cutoffs of Ki-67 LI and SUVmax was defined as ROC curve of Pre LAT1 intensity score 2 < as positive.